CompanyDrug

Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma

CompanyDrug

CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer

CompanyDrug

Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study

CompanyDrug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia

CompanyDrug

Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment

CompanyDrug

Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study

CompanyDrug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

CompanyDeals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

CompanyDrug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

CompanyDrug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization